Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.56 |
| ▸ | MSR1 | P21757 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SI | P14410 | 2/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16749882 | 0.75 | SRC (1.00) | SRCPTPN1MSR1MGAMGAA | |
| SCHEMBL29412614 | 0.75 | SRC (1.00) | SRCPTPN1MSR1MGAMGAA | |
| SCHEMBL31545696 | 0.75 | SRC (1.00) | SRCPTPN1MSR1MGAMGAA | |
| SCHEMBL29571282 | 0.75 | SRC (1.00) | SRCPTPN1MSR1MGAMGAA | |
| SCHEMBL16749879 | 0.75 | SRC (1.00) | SRCPTPN1MSR1MGAMGAA | |
| SCHEMBL14283768 | 0.73 | SRC (0.66) | SRCPTPN1MSR1MGAMGAA | |
| Xanthorrizol SCHEMBL14115131 | 0.72 | SRC (0.56) | SRCPTPN1MSR1MGAMGAA | |
| Xanthorrizol SCHEMBL13816855 | 0.72 | SRC (0.56) | SRCPTPN1MSR1MGAMGAA | |
| Xanthorrizol SCHEMBL14879579 | 0.72 | SRC (0.56) | SRCPTPN1MSR1MGAMGAA | |
| SCHEMBL29966905 | 0.72 | SRC (0.78) | SRCPTPN1MSR1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105051-A1 | COMPOUNDS FOR INCREASING MHC-I EXPRESSION AND MODULATING HISTONE DEACETYLASE ACTIVITY | Cava Healthcare Inc. (CA) | 2022-04-07 | — | — | US | disclosed |
| WO-2020154811-A9 | COMPOUNDS FOR INCREASING MHC-I EXPRESSION AND MODULATING HISTONE DEACETYLASE ACTIVITY | Cava Healthcare Inc. (CA) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020154811-A1 | COMPOUNDS FOR INCREASING MHC-I EXPRESSION AND MODULATING HISTONE DEACETYLASE ACTIVITY | Cava Healthcare Inc. (CA) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105051-A1 | COMPOUNDS FOR INCREASING MHC-I EXPRESSION AND MODULATING HISTONE DEACETYLASE ACTIVITY | HDAC1, TAP1, HDAC11 | SRC 2561/4885PTPN1 2769/4885MSR1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.